

Rezafungin: Adis Evaluation

Key Points

- A once-weekly echinocandin is being developed by Cidara Therapeutics for the treatment of candidaemia and invasive candidiasis, and prevention of invasive fungal diseases in blood and marrow transplant recipients
- Received its first approval on 22 March 2023 in the USA
- Approved in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options

Summary

Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3- β -D-glucan synthase, is being developed by Cidara Therapeutics.

In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.

Rezafungin is also being developed for the prevention of invasive fungal diseases in blood and marrow transplant recipients.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.